Summary
AbbVie Inc.'s 2016 10-K filing reveals a company experiencing robust revenue growth, primarily driven by its flagship product, HUMIRA, which constituted 63% of total net revenues. Significant strategic moves in 2016 included the acquisition of Stemcentrx for approximately $5.8 billion, aimed at bolstering its oncology pipeline with assets like Rova-T. The company also saw substantial growth in IMBRUVICA, following its acquisition of Pharmacyclics, indicating a strengthening position in oncology. Despite revenue growth, AbbVie faced challenges including increased R&D expenses, a notable rise in long-term debt due to acquisitions and financing activities, and ongoing patent expirations, particularly for HUMIRA, which is subject to biosimilar competition and whose composition of matter patent expired in December 2016. The company is actively managing these challenges by investing in its pipeline and returning value to shareholders through dividends and share repurchases. Looking ahead, AbbVie is focused on continued growth from its key products, expanding operating margins through efficiency initiatives, and augmenting its pipeline via strategic licensing and acquisitions. The company anticipates several regulatory submissions and key data readouts in the near future. Investors should monitor the impact of HUMIRA's patent expiry and the competitive landscape, particularly regarding biosimilars, as well as the successful integration and commercialization of recently acquired assets.
Financial Highlights
55 data points| Revenue | $25.64B |
| Cost of Revenue | $5.83B |
| Gross Profit | $19.80B |
| SG&A Expenses | $5.88B |
| Operating Expenses | $16.30B |
| Operating Income | $9.34B |
| Interest Expense | $1.05B |
| Net Income | $5.95B |
| EPS (Basic) | $3.65 |
| EPS (Diluted) | $3.63 |
| Shares Outstanding (Basic) | 1.62B |
| Shares Outstanding (Diluted) | 1.63B |
Key Highlights
- 1AbbVie reported total net revenues of $25.6 billion in 2016, a 12.2% increase year-over-year, largely driven by HUMIRA and IMBRUVICA.
- 2HUMIRA remained the dominant revenue driver, accounting for 63% of total net revenues ($16.1 billion).
- 3The company acquired Stemcentrx for approximately $5.8 billion to expand its oncology pipeline, adding Rova-T and other early-stage assets.
- 4IMBRUVICA sales showed significant growth, more than doubling in 2016, driven by new indications and market share gains.
- 5Research and Development expenses increased to $4.4 billion in 2016, reflecting continued investment in pipeline advancement.
- 6AbbVie's long-term debt increased significantly to $36.5 billion, primarily due to debt issued to finance major acquisitions like Pharmacyclics and Stemcentrx.
- 7The composition of matter patent for HUMIRA expired in December 2016, posing a potential future risk from generic or biosimilar competition.